FDA-approved Digestive & weight

Enlicitide

Enlicitide is an oral macrocyclic PCSK9 inhibitor peptide. It is filed in this library under digestive & weight, a navigation topic rather than a statement of where it acts. As a regulatory matter it has at least one product approved by the FDA.

Regulatory status

Enlicitide has an FDA-approved product on the U.S. market, marketed as Lipfendra Tablet, Film Coated [Merck Sharp & Dohme Llc].

The current label is held by Merck Sharp & Dohme LLC.

The evidence

What has actually been published

2 sources on Enlicitide, each resolved to its journal of record. Titles are listed so you can judge the evidence rather than take a summary on trust.

Nearby

Other peptides acting on digestive & weight

Not sure what applies to you?

A 60-second questionnaire, reviewed by a U.S.-licensed physician.

Find my protocol

Educational reference only. This page explains what has been published about Enlicitide. It is not medical advice, it is not a diagnosis, and it carries no dosing information of any kind. OPTML does not offer or supply this compound unless a product page on this site says otherwise.

Treatment decisions are made by a licensed physician after an individual evaluation. Compounded preparations are not FDA-approved or evaluated by the FDA for safety, effectiveness, or quality. Individual results vary.

All 150 peptides